Mechanism of Action of Eculizumab (Soliris)
Introduction Eculizumab is a humanized monoclonal antibody that selectively binds to complement protein C5, inhibiting its cleavage and preventing terminal complement complex formation. It is approved for paroxysmal nocturnal hemoglobinuria (PNH), atypical hemolytic uremic syndrome (aHUS), generalized myasthenia gravis (gMG), and neuromyelitis optica spectrum disorder (NMOSD). Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route … Read more